Bulk Inquiry
Atorvastatin calcium
- Lipitor
- Parent CAS: 134523-00-5
- Soluble in DMSO
- MF: C33H34FN2O5.0.5Ca
- MW: 577.67
Description
Atorvastatin calcium is a HMG-CoA reductase inhibitor in the statin class. It suppresses cholesterol biosynthesis through the mevalonate pathway and is used to investigate lipid-lowering and pleiotropic statin pharmacology.
HMG-CoA reductase is the rate-limiting enzyme in cholesterol synthesis and a central cardiovascular drug target. Atorvastatin is useful for studying cholesterol metabolism, lipoprotein regulation, endothelial signaling and mevalonate pathway biology.
Key Features
- Statin-class HMG-CoA reductase inhibitor
- Targets cholesterol biosynthesis through the mevalonate pathway
- Relevant to LDL cholesterol and lipid metabolism research
- Useful tool for cardiovascular pharmacology
Applications
- HMG-CoA reductase assays
- Cholesterol biosynthesis studies
- Cardiovascular disease models
- Mevalonate pathway research
More Information
| Parent CAS No. | 134523-00-5 |
|---|---|
| Chemical Name | (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate hemi-calcium salt |
| extra_info | . |
| MFCD | MFCD03613598 |
| Short Description | HMG-CoA inhibitor |
References
- BD Roth. The Discovery and Development of Atorvastatin, a Potent Novel Hypolipidemic Agent. Prog. Med. Chem. 2002, 40, 1–22.
- S Youssef et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420, 78-84.
- HM Colhoun et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004, 364 (9435), 685 - 696.
- PS Sever et al. Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac (...). Drugs 2004, 64 (2 Suppl.), 43-60.
- JC LaRosa et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N. Engl. J. Med. 2005, 352, 1425-1435.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 2047 | Torcetrapib |
From $121.00 |
| 2114 | CP 775146 |
From $121.00 |
| 2216 | CP 346086 |
From $154.00 |
| 2450 | NHI 2 |
From $99.00 |
| 2506 | BMS 303141 |
From $99.00 |
| 2657 | MGL-3196 |
From $99.00 |
| 3240 | Finasteride |
From $55.00 |
| 3443 | Simvastatin |
From $88.00 |
| 3444 | Rosuvastatin calcium |
From $55.00 |
